Malignant tumor
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with advanced malignant tumors confirmed by pathologiccytology combined with previous history and current history; 2.patients over 18 years old, regardless of gender; 3. KPS score greater than 70% or ECOG score less than 1 point; 4.Malignant tumor patients treated with immune checkpoint inhibition; 5.Normal function of major organs: normal thyroid function, normal cardiacfunction (normal range of cardiac troponin, normal electrocardiogram); 6.Renal function needs to meet: serum creatinine value is less than the upperlimit of normal value, endogenous creatinine clearance rate is not less than60ml/min, glomerular filtration The rate is not less than 60ml/min; Liver function: total bilirubin<1.5 times the upper limit; Liver enzymes <1.5 times upper limit; 7.No history of immune-related diseases, such as SLE, autoimmunehepatitis, rheumatoid arthritis, vasculitis, etc. 8. Good compliance and voluntarily accepted follow-up, treatment, laboratory examination and imaging evaluation as planned
Exclusion criteria
Exclusion criteria: 1Patients with known intolerance to thymofasine and immune checkpoint inhibitors; 2Combination of severe and uncontrolled conditions that have occurred in the past as a result oftreatment or disease progression symptoms; 3The presence of unresolved baseline or grade 1 adverse eventsassociated with previous PD-1 treatment; 4Patients requiring maintenance therapy with immunosuppressants, such as thoseundergoing organ transplantation.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Immune cell and molecular counts; | — |
Primary
| Measure | Time frame |
|---|---|
| PFS;ORR;Incidence of adverse reactions; | — |
Countries
China
Contacts
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology